About this item:

328 Views | 63 Downloads

Author Notes:

Address correspondence to: Jack L. Arbiser, Department of Dermatology, Emory University School of Medicine, WMB 5309, 1639 Pierce Drive, Atlanta, Georgia 30322, USA. Phone: 404-727-5063; Fax: 404-727-0923; Email: jarbise@emory.edu.

The author has declared that no conflict of interest exists.

Subjects:

Why targeted therapy hasn't worked in advanced cancer

Tools:

Journal Title:

Journal of Clinical Investigation

Volume:

Volume 117, Number 10

Publisher:

, Pages 2762-2765

Type of Work:

Article | Final Publisher PDF

Abstract:

In this issue of the JCI, Nissen et al. report that a reciprocal interaction exists between the growth factors FGF2 and PDGF-BB, causing tumors to exhibit increased angiogenesis and metastatic potential (see the related article beginning on page 2766). Both FGF2 and PDGF-BB signal through tyrosine kinase receptors, which have been the target of tyrosine kinase inhibitors for cancer therapies. These inhibitors are usually small molecules that inhibit the kinase activity of a receptor or nonreceptor tyrosine kinase, preventing downstream signaling. The results of this study shed light on why tyrosine kinase inhibitors have been useful for the treatment of only a small number of advanced cancers. Currently, a major focus of pharmaceutical companies is to develop ever more potent and specific tyrosine kinases. The results presented here suggest that this approach may not be successful.

Copyright information:

© 2007, American Society for Clinical Investigation

Export to EndNote